SENSCIS
Nintedanib in Systemic Sclerosis-Associated ILD
Patient / Population Intervention / Exposure Comparison Outcome
In 576 patients with SSc-associated ILD, nintedanib slowed annual FVC decline compared with placebo.
N
576
Design
Multicentre RCT
Endpoint
Annual rate of FVC decline
Relevance
3
Result-52.4 vs -93.3 mL/year (44% reduction; p=0.04).
Distler O, et al. N Engl J Med. 2019;380(26):2518-2528. 10.1056/NEJMoa1903076
Discussion & critique
Third FDA indication for nintedanib.